Oxford BioMedica PLC (LSE:OXB) - Share price


Stock Report

Oxford BioMedica PLC OXB

Last Price
GBX1,356.00

Day Change
-10.00|-0.73%

As of 26/11/2021
18:02:27 GMT | GBX
Minimum 15 Minutes Delay.

Last Close1,366.00p
Day Range1,319.23 - 1,380.00
Mkt Cap1.17Bil
52-Wk Range810.00 - 1,678.00
Yield %-
ISINGB00BDFBVT43
Volume78,625
P/E61.35
P/S0.12
P/CF3.48

Share Price

Total Returns 26/11/2021

 Chg (%)  
More ...
Oxford BioMedica PLC-11.37 
FTSE 100 TR GBP-2.91
 
Financials
201820192020
More ...
Income Statement
Turnover66.7864.0687.73
Operating Profit7.93-12.58-4.86
Net Profit7.54-16.07-6.25
Reported EPS10.89-22.10-7.81
Balance Sheet
Current Assets65.5356.94107.95
Non Current Assets46.8765.9975.98
Total Assets112.40122.93183.93
Current Liabilities28.5128.9452.46
Total Liabilities77.6647.3071.18
Total Equity34.7475.63112.75
Cash Flow
Operating Cash Flow9.21-6.64-3.89
Net Change in Cash17.92-16.0030.50

Regulatory News

DateAuthor Headline
10/08/2018Emma Simon Investor Views: Will Rolls Royce Shares Deliver an Early Retirement?
Private investor Jon Batley is building a share portfolio which he hopes will allow him to retire early
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
29/09/2021PurchaseDr. Michael Hayden, Ch.B.,M.B.,PhD1,507.501,91028,793.00
23/06/2021PurchaseDr. Heather Preston, M.D.1,288.002,23528,787.00
23/06/2021PurchaseDr. Siyamak Rasty1,288.002,23528,787.00
30/11/2020SaleDr. Andrew John William Heath869.0015,756136,920.00

Company Profile

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focusses on the field of immunotherapy by managing a platform of technologies in designing gene-based medicines. The company operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of revenue from Europe.

Sector

Biotechnology

Index

FTSE 250 , FTSE 350 , FTSE All Share , FTSE techMARK Focus , FTSE techMARK All Share

Next Event 14/04/2022

Final Results
Ratios
Comp
More ...
PER (E)68.44
Div Yld (E)0.00
PEG (E)0.00
ROCE-4.31
Op Mrgn-0.06
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Executive Director, Chief Executive OfficerMr. John Dawson
Non-Executive DirectorDr. Michael Hayden, Ch.B.,M.B.,PhD
Non-Executive DirectorDr. Heather Preston, M.D.
Non-Executive Director, Senior Independent Director Deputy ChairmanMr. Stuart Henderson
Executive Director, Chief Financial OfficerMr. Stuart Paynter
Non-Executive DirectorDr. Siyamak Rasty
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.